![]() |
Duvelisib
- 英文名称:Duvelisib
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11406
- cas:1201438-56-3
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-04-30
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11406 |
用途 | 科研检测 |
英文名称 | Duvelisib |
包装规格 | 1MG |
CAS编号 | 1201438-56-3 |
别名 | Duvelisib |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:98% by HPLC;NMR (Conforms)
分子式:C22H17ClN6O
分子量:416.87
溶剂:DMSO (>25 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):PI3K δ/γ inhibitor
Function / Pharmacology:Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2 Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, ande others.3,4 Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5 Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes
分子式:C22H17ClN6O
分子量:416.87
溶剂:DMSO (>25 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):PI3K δ/γ inhibitor
Function / Pharmacology:Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2 Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, ande others.3,4 Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5 Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes